Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > Analyst Report

<< Previous

Bullboard Posts

Next >>

Post by steadfaston Apr 04, 2021 4:20pm

305 Views

Post# 32935365

Analyst Report

I am surprised one of the Director's or the lawyer did not suggest in the bot deal
a clause be inserted:
SVA to issue the share and wt certificates for compensation to Cannacord
upon receipt of Cannacord Analyst Report. (The lawyer can dress the
sentence up to ensure legality)
No report - no shares & wts - plain and simple

March 1, 2021 Closing of Bot Deal
We are still waiting for Analyst Report. Cannacord will have "no sense of urgency"
they have received their payment, on to the next bot deal.
Happy Easter to all.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?